Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided for treating biofilms without inducing antimicrobial resistance.

A personal cleansing composition includes a surfactant system, wherein the surfactant system includes from 0.1% to 5% of a fatty acyl isethionate surfactant by weight of the composition; from 0.5% to 40% of a co-surfactant by weight of the composition; from 0.05% to 5% of a natural polysaccharide or a chemically modified natural polysaccharide by weight of the composition; wherein the personal cleansing composition includes a first and second phase, wherein the first phase is an isotropic and micellar surfactant phase; wherein the second phase is a polymer liquid crystalline phase; wherein the composition is free of alkyl sulfate and alkyl ether sulfate type of surfactants; wherein the composition exhibits a yield stress value τ.sub.y from 0.005 Pa to 3 Pa; and wherein the composition exhibits a flow viscosity from 3 Pa.Math.s to 100 Pa.Math.s at 25° C. at a shear rate of 1.5 s.sup.−1.

Methods for treating or preventing viral infection-induced symptoms are disclosed. Methods for treating or preventing a viral infection are disclosed. Methods for treating or preventing mitochondrial dysfunction are disclosed. The viral infections include SARS-CoV-2, HIV, Influenza, and MERS. The methods include administering an emblica extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of an emblica extract, a fucus extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a fucus extract, or a chebula extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a chebula extract.

Cosmetic emulsions are disclosed that can remain stable even with relatively high salt based cosmetic astringent content. In one aspect, an emulsion can include a water phase including water and a rheology modifier including Microcrystalline Cellulose and Cellulose Gum. The emulsion can also include an oil phase comprising Steareth-2 and Glyceryl Stearate and an emulsifier selected from the group consisting of: Steareth-20, Steareth-21, and combinations thereof. The emulsion can include a salt based cosmetic astringent providing at least about 1.0% of the emulsion by weight.

A method for reducing dental disease in a patient comprises a patient wearing in the patient's mouth an appliance containing an oral care product comprising a carrier and an anti-dental disease agent with a pH above 7.0. The appliance brings the patient's teeth in direct and sustained contact with the product and is custom made for each individual patient. The oral care product is specifically prescribed and formulated for the particular dental disease of that individual patient.

Provided is a cleaner composition which causes no malfunction due to clogging even when contained in a pump foamer container, or the like, and repeatedly used, and is excellent in resilience and persistence of foam, and feeling after washing off. The cleaner composition includes a soap that is obtained by neutralizing a higher fatty acid with sodium N-methyltaurate, and a polymer including dimethyl diallyl ammonium chloride as a monomer unit and having a molecular weight of 200000 or less.

The present invention addresses the issue of providing an external composition for screen foamers such as pump foamers, that can be safely used even when not removed after application. Provided is an external composition for screen foamers, including a non-ionic surfactant as a foaming component and, ideally, being in a soluble state.

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

The present disclosure relates method of tanning a person including applying a moisturizer to an applicator and applying a tanning solution to the applicator. The moisturizer and the tanning solution are applied to the applicator in separate steps. The applicator is then contacted onto the skin of a person to apply the moisturizer and tanning solution.